Company Research Report: Genome International Corp
Company Overview
Name
Genome International Corp
Mission
Genome International aims to empower hospitals and researchers globally to uncover clinically relevant information within the genome, bridging the gap from bench to bedside and improving patient lives worldwide.
Founded
No information is available.
Founder(s)
No information is available.
Key People
- Periannan Senapathy, PhD - Founder & President
- Robert S. Langer, ScD. - Founder of Moderna, Professor at MIT
- James Lupski, MD, PhD, DSc. - Chair of Molecular Genetics, Baylor College of Medicine
- Raphael Pollock, MD, PhD - Director of Cancer Center, The Ohio State University
- Mohan Ananda, PhD, J.D. - Founding CEO, Stamps.com
- Ravishankar Iyer, PhD - Director of CCBGM, University of Illinois Urbana-Champaign
- Bijal Parikh, M.D., PhD - Director of Molecular Diagnostics, Washington University
Headquarters
8000 Excelsior Drive, Suite 202, Madison, WI 53717, USA
Number of Employees
No information is available.
Revenue
No information is available.
Known For
Genome International is known for its innovative software products and services in clinical genomics and Information Technology. It provides clinical decision support tools, revealing crucial information about druggable genes, adverse drug reactions, clinical trials, and more.
Products
Whole-Genome Technologies
Genome International has developed methodologies to analyze the entire human genome, including both coding and non-coding regions, unlike traditional software that focuses on less than 2% of the genome.
Genome Explorer®
- Description: A cloud-based clinical genomics platform for precision medicine.
- Key Features:
- Rapid analysis of whole genome data.
- Generates accurate and intuitive clinical reports.
- Integrates patient sequence data with electronic health records (EHR).
- Provides genetic details of diagnosis, therapeutics, and pharmacogenomics.
- Incorporates artificial intelligence (AI) for enhanced genomic analysis.
- Comprehensive visualization of genetic mechanisms of disease causation and drug responses.
Cancer Diagnosis and Therapeutics
- Description: Identifies somatic and germline mutations, gene fusion events, CNVs, and structural variants.
- Key Features:
- Transforms tumor DNA to a clinical report.
- Adheres to NCCN, ASCO & ESMO guidelines.
- Includes FDA-approved drugs, dosage, drug adverse effects, and relevant clinical trials.
Inherited Disorders
- Description: Sequences and discovers genetic germline candidate mutations from various Mendelian disorders.
- Key Features:
- Inbuilt standard inherited disorder panels.
- Reports significant mutations in accordance with ACMG/AMP guidelines.
- Provides up-to-date information from relevant annotation sources.
Cohort Genome Explorer™
- Description: Analyzes large genetic datasets to discover disease-causing genes rapidly.
- Key Features:
- Reduces the analysis time from months or years to just a day or two.
- Utilizes novel algorithms and powerful cloud computing technologies.
Clinical Trial Genomics
- Description: Enhances drug development by discovering genes and mutations responsible for drug response phenotypes.
- Key Features:
- Yields more successful drug candidates.
- Develops drugs with the least side effects.
Health-IT Solutions
- Description: Develops custom healthcare applications for secure management of large-scale medical information.
- Key Features:
- Solutions in big data analytics, managed IT services, technology consulting, enterprise solutions, and cloud data migration services.
Recent Developments
New Products Launched
- Genome Explorer®: Launched as a comprehensive platform for clinical genomic analysis.
New Features Added to Existing Products
- Genome Explorer®: Integrated several novel algorithms and advanced AI technologies for improved efficiency and precision in genomic analysis.
New Partnerships
No information is available.
Other Developments
No information is available.
© 2024. Genome International Corp. All Rights Reserved.
